PBX 003
Alternative Names: PBX-003Latest Information Update: 16 Jul 2024
Price :
$50 *
At a glance
- Originator Pinotbio; ProEn Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Jul 2024 Preclinical trials in Solid tumours in South Korea (Parenteral) (Pinotbio pipeline, July 2024).
- 31 Dec 2021 Early research in Solid tumours in South Korea (Parenteral), prior to December 2021 (Pinotbio pipeline, December 2021)